BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 23819361)

  • 1. [Outcome after radical prostatectomy with extended pelvic lymphadenectomy for untreated high-risk clinically localized prostate cancer].
    Tsurusaki T; Yamasaki Y; Maruta S
    Nihon Hinyokika Gakkai Zasshi; 2013 May; 104(3):496-504. PubMed ID: 23819361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
    Heidenreich A; Varga Z; Von Knobloch R
    J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy.
    Arenas LF; Füllhase C; Boemans P; Fichtner J
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S10-4. PubMed ID: 20094944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients.
    Salomon L; Hoznek A; Lefrère-Belda MA; Bellot J; Chopin DK; Abbou CC
    Eur Urol; 2000 Mar; 37(3):297-300. PubMed ID: 10720855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.
    Gandaglia G; De Lorenzis E; Novara G; Fossati N; De Groote R; Dovey Z; Suardi N; Montorsi F; Briganti A; Rocco B; Mottrie A
    Eur Urol; 2017 Feb; 71(2):249-256. PubMed ID: 27209538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of pelvic lymphadenectomy in the therapy of prostate and bladder cancer].
    Heidenreich A; Ohlmann CH
    Aktuelle Urol; 2005 Jun; 36(3):219-29. PubMed ID: 16001337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    Preisser F; van den Bergh RCN; Gandaglia G; Ost P; Surcel CI; Sooriakumaran P; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Salomon L; Ploussard G; Tilki D;
    J Urol; 2020 Feb; 203(2):338-343. PubMed ID: 31437119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indications for pelvic lymphadenectomy in clinically localized prostate cancer].
    Peneau M; Villers A; Molinié V; Theis D; Soulié M
    Prog Urol; 2004 Jun; 14(3):287-94. PubMed ID: 15373168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Aug; 12(8):739-44. PubMed ID: 16174048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer.
    Yuh BE; Ruel NH; Mejia R; Novara G; Wilson TG
    BJU Int; 2013 Jul; 112(1):81-8. PubMed ID: 23351148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy].
    Miyamae K; Kitani K; Miyamoto K; Hamada S; Kawano T; Maehara A; Otsuka Y; Otsuka T; Hamada Y
    Nihon Hinyokika Gakkai Zasshi; 2009 Jul; 100(5):570-5. PubMed ID: 19663244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
    Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
    Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer.
    Yuh BE; Ruel NH; Mejia R; Wilson CM; Wilson TG
    Eur Urol; 2012 May; 61(5):1004-10. PubMed ID: 22366188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.